RT Book, Section A1 Zeybek, Burak A1 Ratner, Elena A2 Llor, Xavier A2 Hofstatter, Erin Wysong SR Print(0) ID 1182365823 T1 Risk Assessment and Clinical Management – Ovarian Cancer T2 Cancer Genetics: A Clinical Approach YR 2022 FD 2022 PB McGraw Hill PP New York, NY SN 9781260440270 LK hemonc.mhmedical.com/content.aspx?aid=1182365823 RD 2024/03/28 AB Ovarian cancer is the second most common gynecologic malignancy and the most common cause of death from gynecologic cancer in the United States with 22,240 new cases and 14,000 deaths annually.1 It is the fifth leading cause of cancer death in women after cancers of the breast, lung, and endometrium. Based on the National Cancer Database Surveillance, Epidemiology, and End Results (SEER) data from 2011 to 2015, the lifetime risk of developing ovarian cancer is 1.3%, and the median age at diagnosis is 63. The number of new cases and deaths are reported to be 11.6 and 7.2 per 100,000 women per year, respectively.2